Lonza to Host New Webinar â€“ â€œStreamlining Your QC Testing: Automated Endotoxin Testing and Process Optimizationâ€
Cologne (DE) / Walkersville, MD (USA), 09 October 2018 – On 23 October 2018, Lonza is hosting a free 60-minute webinar showing how automated endotoxin testing enables the optimization of QC processes and improves data integrity.
Reliable endotoxin testing of in-process water and end products is very important to the parenteral, medical device, dialysis, radiopharmaceutical and compounding industries to measure compliance with the United States Pharmacopeia (USP) Chapter 85 Bacterial Endotoxins Test. However, conventional manual-testing methods are prone to human error, as well as time and resource inefficiencies, which can jeopardize data integrity and ultimately put patient safety at risk.
Titled “Streamlining Your QC Testing: Automated Endotoxin Testing and Process Optimization,” the webinar will be presented by Allen Burgenson, Subject Matter Expert for Endotoxin Testing at Lonza. During the webinar he will discuss:
- The challenges associated with manual endotoxin testing steps, including potential data integrity issues
- What is endotoxin assay automation?
- Ease of integrating automation into the QC testing workflow
- How automation of the liquid-handling step can save time and reduce manual pipetting errors and the need for retesting
- The global need for automation and the move toward Industry 4.0 and the U.S. Food and Drug Administration (FDA) Process Analytical Technology (PAT) Initiative
- How to further optimize the QC testing process by using Lonza’s WinKQCL™ Endotoxin Detection and Analysis Software, and how this solution can facilitate regulatory compliance
During the webinar Burgenson will also present a case study demonstrating the benefits of automated versus manual endotoxin testing.
Anyone interested in attending the webinar can register here.
Date: Tuesday, 23 October 2018
8 AM PDT (Los Angeles)
11 AM EDT (New York)
4 PM BST (London)
5 PM CEST (Berlin)
Further information can be found on the WinKQCL™ Endotoxin Detection Software product page. By registering interest in the webinar, participants will also receive a link once it is available to view “on demand” via the Lonza website.
More information about Lonza’s upcoming webinars is available here: www.lonza.com/webinars.
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer's healthy environment.
Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.
Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at www.lonza.com
Lonza Contact Information
Lonza Cologne GmbH
Manager Marketing Communications
Tel +49 221 991990
Lonza Group Ltd
Head External Communications
Tel +41 61 316 8840
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.